ACM
IOVA icon

AlphaCrest Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

AlphaCrest Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,488
Closed -$148K – 566
2022
Q3 		$148K Buy
15,488
+2,803
+22% +$32.3K 0.01% 1246
2022
Q2 		$140K Sell
12,685
-4,853
-28% -$63.6K 0.01% 1224
2022
Q1 		$292K Buy
17,538
+1,838
+12% +$28.4K 0.02% 1110
2021
Q4 		$300K Buy
15,700
+4,287
+38% +$94.4K 0.01% 1256
2021
Q3 		$281K Buy
+11,413
New +$269K 0.01% 1130
2021
Q2 		– Sell
-12,900
Closed -$408K – 1287
2021
Q1 		$408K Buy
12,900
+800
+7% +$33.2K 0.02% 897
2020
Q4 		$561K Buy
12,100
+1,100
+10% +$43.7K 0.05% 588
2020
Q3 		$362K Buy
+11,000
New +$337K 0.04% 771
2020
Q2 		– Sell
-9,500
Closed -$284K – 1003
2020
Q1 		$284K Buy
+9,500
New +$252K 0.03% 820
2019
Q4 		– Sell
-12,000
Closed -$218K – 1305
2019
Q3 		$218K Buy
+12,000
New +$265K 0.01% 1191

Other funds holding IOVA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AlphaCrest Capital Management's IOVA Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q4 2022, closing a stake of 15,488 shares — an estimated $148K sold.

AlphaCrest Capital Management first reported a position in IOVA in Q3 2019 and held it in 10 quarters. The position peaked at $561K in Q4 2020. 218 funds tracked by Wall St. Rank hold IOVA as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Iovance Biotherapeutics position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 15,488 Iovance Biotherapeutics shares in Q4 2022, an estimated $148K.
  • AlphaCrest Capital Management first reported a position in Iovance Biotherapeutics in Q3 2019 and held it in 10 quarters.
  • AlphaCrest Capital Management's Iovance Biotherapeutics position peaked at $561K in Q4 2020.
  • 218 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.